EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy09:45 - 18:008/07/2022Location: Exhibit Hall - Hall BNot for CME CreditType: E-PosterTrack: Metastatic Non-small Cell Lung Cancer - Immunotherapy+EP08.01-109 - TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLCPresenter: Martin Forster | Author(s): Matthew Krebs, Margarita Majem, Julio Peguero, Tim Clay, ENRIQUETA FELIP, Wade Iams, Patricia Roxburgh, Bernard Doger, Pawan Bajaj, Joanna Kefas, Julie Ann Scott, Andrés Barba Joaquín, Christian Mueller, Frederic Triebel
Vienna presentation > new data ? .
Ann: TACTI-002 2nd line lung cancer data presented at 2022 WCLC, page-25
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 286261 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 253490 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |